Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment

Reporter Kim Jisun / approved : 2023-10-13 03:07:11
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.

According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.

Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.

Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Lotte Chilsung to Offer First-Ever Voluntary Retirement Program in 75 Years2025.11.07
Police Refer Former Doosan Bobcat Korea Executives to Prosecutors Over Bid-Rigging and Bribery Allegations2025.11.07
SK Group to Launch Early Year-End Executive Reshuffle; Major Layoffs Expected at SK Telecom2025.11.07
KT Accused of Concealing 2024 Malware Infection Affecting Subscriber Data; Government Probe Finds Security Failures Behind Micropayment Hacking2025.11.07
Korea’s National Pension Service Gains Strong Q3 Returns from U.S. Tech Stocks Amid Market Rally2025.11.07
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사